Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Jackisch C, Schneeweiss A, Denkert C, Engels K, Klare P, Fasching P, Burchardi N, Loibl S, Von Minckwitz G (2016)
Publication Type: Conference contribution
Publication year: 2016
Book Volume: 57
Pages Range: S98-S99
APA:
Paepke, S., Huober, J., Sherko, K., Eidtmann, H., Untch, M., Costa, S.D.,... Von Minckwitz, G. (2016). Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE). (pp. S98-S99).
MLA:
Paepke, S., et al. "Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE)." 2016. S98-S99.
BibTeX: Download